Answers are grounded in this paper and cite their sources.
In vitro and in vivo analysis shows Ganoderma lucidum spores inhibit cancer cell proliferation and support apoptosis, indicating potential therapeutic benefits for papillary thyroid cancer.
Abstract Ganoderma lucidum wall-broken spores (BGLSP), traditionally used in Traditional Chinese Medicine for immunity and chronic diseases, contain bioactive triterpenoids with anti-tumor potential, but their mechanisms against papillary thyroid cancer (PTC) remain unclear. This study aimed to investigate the anti-tumor effects of BGLSP on PTC, focusing on its ability to modulate cellular proliferation, apoptosis, migration, and the epithelial-mesenchymal transition (EMT) pathway. Three PTC cell lines (TPC-1, K1, KTC-1) were treated with BGLSP (0.5–4 mg/mL) to assess viability (CCK-8 assay), proliferation (colony formation, Ki-67 immunofluorescence), apoptosis (flow cytometry, caspase activation), and migration (wound healing, transwell assays). Western blot analyzed EMT markers (E-cadherin, N-cadherin, Vimentin, ZO-1), while a nude mouse xenograft model assessed BGLSP efficacy (2 mg/kg). BGLSP significantly inhibited PTC cell proliferation and colony formation while inducing apoptosis via caspase-8/caspase-3 activation. It suppressed migration by reversing EMT, upregulating epithelial markers (E-cadherin, ZO-1), and downregulating mesenchymal markers (N-cadherin, Vimentin). In vivo, BGLSP reduced tumor growth and Ki-67 expression, corroborating in vitro findings. BGLSP demonstrates anti-tumor effects in PTC by targeting proliferation, apoptosis, and EMT, supporting its traditional use. These findings highlight its potential as a natural adjuvant therapy, warranting further study of active compounds and clinical applications.
No takes yet. Share an insight, caveat, or question.
Shi et al. (2025) studied this question.
Synapse has enriched 8 closely related papers on similar clinical questions. Consider them for comparative context: